Navigation path



Recombinant Measles Virus as a Vector for HIV Vaccines
Framework programme:
Project number:
EC contribution:
€ 5 500 000
49 months
Starting date:
January 2006

Keywords: HIV; AIDS; vaccine; recombinant measles virus


This proposal aims at demonstrating the safety and immunogenicity in humans of a novel recombinant measles virus (MV) vector for use as an AIDS vaccine. The vector is replication competent in vivo and is derived from a widely used measles vaccine strain (Schwarz), which is known to induce very long lasting immunity. Therefore, this novel vector potentially offers a unique combination of safety and potency. The recombinant HIV MV vectors will express three relatively conserved HIV proteins (Gag, Pol, Nef) from HIV clade B and A strains. A good manufacturing practices (GMP) compatible production process for the recombinant MV vector will be developed and a GMP lot will be produced for two clinical studies. The first study will evaluate the safety profile of the MV vector, while the second study will also assess the immunogenicity in MV-immune volunteers. With these two clinical studies, the project will specifically address potential shedding of the recombinant vector into the environment and the potential negative impact of pre-existing MV immunity. It is expected that at the end of the project sufficient clinical data on the safety and immunogenicity will have been generated to decide on subsequent advanced technical and clinical development of this novel vaccine approach.

[+] Read More